Antibody-drug conjugate · Cytotoxic, directed at CD74 · developed by Sutro Biopharma
Bezetabart Debotansine is an antibody-drug conjugate in which an anti-CD74 antibody is site-specifically linked to a non-cleavable maytansinoid microtubule-disrupting warhead. After binding CD74 on tumor cells and internalization, the maytansinoid inhibits cell division and growth. It is studied in B-cell lymphomas and multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03424603 | Phase 1 | B-cell Lymphoma | Completed | STRO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
B Cells--TumorsB-cell LymphomaDiffuse Large B Cell LymphomaFollicular LymphomaIndolent LymphomaMantle Cell LymphomaMultiple MyelomaNon Hodgkin Lymphoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the STRO page.
See STRO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
STRO catalysts and pipeline →